Johnson & Johnson (NYSE:JNJ) is currently addressing shareholder proposals regarding executive compensation and human rights ...

Additionally, the company is expanding its SPRAVATO buy-and-bill rollout ... to Greenbrook has increased total shares outstanding by 84%, leading to dilution for existing shareholders.

Spravato recorded sales of $297.0 million ... marginally missing the Zacks Consensus Estimate of $88.84 billion. Sales were slightly ahead of the guidance range of $88.4 billion-$88.8 billion.

Additionally, the company is expanding its SPRAVATO buy-and-bill rollout ... 25.3 million STIM shares to Greenbrook has increased total shares outstanding by 84%, leading to dilution for existing ...

Spravato – based on a fast-acting version of ketamine – was the pathfinder for the category and after a slow start commercially brought in $689 million for J&J last year, an 84% increase on ...

Spravato (esketamine) has possible interactions with alcohol, some other drugs, and certain supplements. Examples include Adderall and benzodiazepines such as clonazepam (Klonopin). Talk with your ...